New England Journal of Medicine A study published in the "New England Journal of Medicine" reports that the RAS inhibitor drug daraxonrasib, which was approved by the U.S. Food and Drug Administration as a treatment for metastatic pancreatic cancer, also shows promise against lung cancer. Sources: NBC News Nature